Lixte Biotechnology Holdings, Inc.

NASDAQ: LIXT · Healthcare · Biotechnology

PublicHQ Pasadena, CA · Los AngelesCIK 0001335105Reports USD

#988 of 1,394 Healthcare companies by revenue

EA Score

41D

FH 44DQ 36GM —SS 46

v0.1 · 55/100 weight · provisional

↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$6.1M

Employees

Market cap

$89.1M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$200.0k$200.0k2015

Net income-$6.1M-$6.1M2025

Operating income-$5.1M-$5.1M2025

Total assets$12.7M$12.7M2025

Liabilities$1.8M$1.8M2025

Equity$9.7M$9.7M2025

Revenue trend

FY2011 – FY2015 · USD

FY11

FY12

FY13

$200.0k

FY15

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Lixte Biotechnology Holdings, Inc. booked $200.0k in FY2015 revenue — among the slowest-growing Healthcare companies we track, at a -3039.3% net margin.

Peers · Healthcare

Seer, Inc.49D Kalaris Therapeutics Inc30D Neonc Technologies Holdings, Inc.10D MAIA Biotechnology, Inc.34D

Neighbors

Los Angeles →

The Walt Disney Company$94.4B71B Rocket Lab USA, Inc.$601.8M50D Public Storage$4.8B79B+Live Nation Entertainment, Inc.$25.2B76B+Ares Management Corporation$5.6B67B Edison International$19.3B81B+

Key facts

CEOGeordan G. Pursglove

SectorHealthcare

IndustryBiotechnology

HeadquartersPasadena, CA

ExchangeNASDAQ: LIXT

Employees2

IPO date2007-10-25

Latest filings

8-K2026-07-10 8-K2026-07-02 8-K2026-06-18 8-K2026-06-16 8-K2026-06-04 8-K2026-06-01 10-Q2026-05-14 8-K2026-04-17

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.